オプションチェーンは、Aclarionの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Aclarionの市場センチメントを評価します。.

Aclarion (NASDAQ:ACON) 株価情報, オプションチェーン

Aclarion

Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The Company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.

Aclarion Inc

HC Wainwright &amp; Co. analyst Edward White reiterates TG Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>) with a Buy and maintains $55 price target.

News

Price Target

Reiteration

Analyst Ratings

TGTX

HC Wainwright & Co. Reiterates Buy on TG Therapeutics, Maintains $55 Price Target

Sea Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SE#NYSE">SE</a>) ("Sea" or the "Company") today announced its financial results for the fourth quarter and full year ended December 31, 2024.
"We delivered a great 2024 with all three businesses going back to strong, double-digit growth, exceeding our original guidance. It was also our second consecutive year of annual positive profit, with all three of our businesses recording positive adjusted EBITDA," said Forrest Li, Sea's Chairman and Chief Executive Officer.
On e-commerce, he said, "GMV grew 28% year-on-year to surpass US$100 billion, and we achieved adjusted EBITDA profitability in both Asia and Brazil. We remain confident about our ability to continue delivering profitable growth in 2025 and expect Shopee's full year 2025 GMV growth to be around 20%, with improving profitability."
Regarding digital financial services, Mr. Li shared, "We delivered exceptional loan book growth of more than 60% year-on-year in the fourth quarter, surpassing US$5 billion as of the end of 2024, making us one of the largest consumer lending businesses in Southeast Asia. While we have scaled fast, risk management remains to be our top operational priority. In 2025, we expect loan book size to grow meaningfully faster than Shopee's GMV annual growth rate, as we improve credit penetration both on- and off-Shopee."
On digital entertainment, Mr. Li said, "2024 was a great year for Garena, marking Free Fire's remarkable comeback with annual bookings growing at 34% year-on-year. Looking ahead into 2025, we will continue scaling our user base and broadening our content offerings. We now expect Garena to grow double digit year-on-year, for both user base and bookings in 2025."

Guidance

Sea Expects Shopee's 2025 GMV Growth Of ~20% With Improving Profitability And Garena To Grow Double DigitFor Both User Base And Bookings

UBS analyst Manav Gupta downgrades Green Plains (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPRE#NASDAQ">GPRE</a>) from Buy to Neutral and announces $7 price target.

Downgrades

GPRE

UBS Downgrades Green Plains to Neutral, Announces $7 Price Target

Health Care

General

NNVC

NanoViricides' NV-387 Promises To Be An Effective Drug To Treat Measles

Pet Valu Hldgs (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PET#TSX">PET</a>) reported quarterly earnings of $0.45 per share which beat the analyst consensus estimate of $0.40 by 12.5 percent. This is a 16.67 percent decrease over earnings of $0.54 per share from the same period last year. The company reported quarterly sales of $295.15 million which beat the analyst consensus estimate of $291.97 million by 1.09 percent. This is a 2.87 percent increase over sales of $286.91 million the same period last year.

Earnings

Earnings Beats

TSX:PET

Pet Valu Hldgs Q4 Adj CAD $0.45 Beats $0.40 Estimate, Sales CAD $295.15M Beat $291.97M Estimate

The Company has the following expectations for full-year 2025:
<ul>
<li>A modest increase in the Company's operating margin rate compared to full-year 2024</li>
<li>An effective tax rate of 23 to 24 percent</li>
</ul>

Target Expects FY25 Net Sales Growth In Range Around 1%, Reflecting Comparable Sales Growth Around Flat; Adjusted EPS Of $8.80 - $9.80 (Est $9.31)

InfuSystem is providing annual guidance for the full year 2025 with net revenue growth estimated to be in the 8% to 10% range. We are also forecasting Adjusted EBITDA margin (non-GAAP) to be in the high-teens, exceeding the Company's margin of 18.8% in 2024, this despite the planned continued investment in the Company's information technology systems. The Company intends to update its annual guidance throughout the year.&nbsp;

INFU

InfuSystem Estimates 2025 With Net Revenue Growth Of 8% To 10%, With Adjusted EBITDA Margin To Be In The High-Teens

UBS analyst William Grippin downgrades Sunnova Energy Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) from Buy to Neutral and lowers the price target from $5 to $0.65.

NOVA

UBS Downgrades Sunnova Energy Intl to Neutral, Lowers Price Target to $0.65

HC Wainwright &amp; Co. analyst Edward White reiterates Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) with a Buy and maintains $51 price target.

SNDX

HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $51 Price Target

Target Reports Q4 Comparable Sales Growth Of 1.5%, Reflected Strong Traffic And Digital Performance

Earnings Misses

Sea Q4 2024 GAAP EPS $0.39 Misses $0.40 Estimate, Sales $4.950B Beat $4.623B Estimate

InfuSystems Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INFU#AMEX">INFU</a>) reported quarterly earnings of $0.04 per share which missed the analyst consensus estimate of $0.07 by 42.86 percent. The company reported quarterly sales of $33.85 million which missed the analyst consensus estimate of $34.90 million by 3.02 percent. This is a 6.54 percent increase over sales of $31.77 million the same period last year.

InfuSystems Holdings Q4 2024 GAAP EPS $0.04 Misses $0.07 Estimate, Sales $33.85M Miss $34.90M Estimate

AI Detection firm, Copyleaks has found that the text generated by DeepSeek-R1 and OpenAI&#8217;s ChatGPT has &#8220;Stylistic overlaps&#8221; in 74.2% of instances.
What Happened: A study conducted by Copyleaks showed that Chinese start-up firm, DeepSeek-R1&#8217;s text generation closely mirrored OpenAI&#8217;s style in over 74% of cases. This suggests that DeepSeek may have relied on OpenAI's model during its training without authorization, according to the report.
The study employed three AI classifiers to accurately analyze stylistic fingerprints, allowing for model-specific attribution. This plays a vital role in safeguarding intellectual property and fostering ethical AI development.
DeepSeek and OpenAI did not immediately respond to <a href="http://pro.benzinga.com">Benzinga&#8217;s</a> request for comment. 
Interestingly, the written text produced by most other models was easily identifiable as unique to each one, except DeepSeek. For instance, Microsoft&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) Phi-4 and Grok-1 models exhibited no similarities to existing models, confirming it was trained independently.
The majority of DeepSeek&#8217;s outputs were identified as being generated by OpenAI&#8217;s models. &nbsp;&#8220;While this similarity doesn&#8217;t&nbsp;definitively prove or declare DeepSeek&nbsp;as a derivative, it does&nbsp;raise questions about its development,&#8221; said&nbsp;Shai Nisan,&nbsp;Head of data science at&nbsp;Copyleaks.
SEE ALSO: <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44075328/eric-trump-says-timing-of-strategic-bitcoin-xrp-cardano-reserve-announcement-was-a-win-for-retail-investors">Eric Trump Says Timing Of Strategic Bitcoin, XRP, Cardano Reserve Announcement Was A &#8216;Win&#8217; For Retail Investors</a>
Why It Matters: This revelation comes at a time when the AI industry is under scrutiny. Recently, Singapore authorities launched an investigation into potential <a href="https://www.benzinga.com/25/03/44076579/singapore-investigates-potential-fraud-in-nvidia-ai-chip-shipments-the-question-is-whether-malaysia-was-a-final-destination">fraudulent activities </a>related to the shipment of&nbsp;Nvidia Corp.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) chips.
Furthermore,&nbsp;Dario Amodei, CEO of Jeff Bezos-backed Anthropic, has called for stronger U.S. AI safeguards. He warned that autocratic regimes like <a href="https://www.benzinga.com/25/03/44069535/anthropic-ceo-dario-amodei-pushes-for-stronger-us-ai-safeguards-saying-autocracies-like-china-and-russia-could-use-ai-to-expand-their-power">China and Russia </a>could use AI to enhance their control and military capabilities.
While the possibility of both AI models being trained using intersecting datasets cannot be ruled out, there could be deeper nuances. "Even if large language models draw from overlapping datasets, AI fingerprinting remains crucial. The sheer variety of elements—such as architecture, fine-tuning methods and generation techniques—ensures that each LLM develops a distinct writing style,&#8221; explains Nisan.
The DeepSeek-R1 and OpenAI similarity issue underscores the need for clear regulations and transparency in AI development to prevent potential misuse and protect intellectual property. It also brings into question DeepSeek R1&#8217;s perceived level of innovation.
Nisan cautioned that this could have significant implications for the AI industry, if not regulated.
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/25/03/44101621/deepseek-loses-top-spot-as-tencents-yuanbao-ai-becomes-no-1-iphone-app-amid-intensifying-ai-battle">DeepSeek Loses Top Spot As Tencent&#8217;s Yuanbao AI Becomes The Top iPhone App In China Amid Intensifying AI Battle</a></li>
</ul>
Image Via Midjourney, Shutterstock

Equities

Markets

Tech

MSFT

NVDA

74% Of DeepSeek's Output Mimics OpenAI's ChatGPT, New Study Reveals: 'It Does Raise Questions About Its Development'

Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) reported quarterly earnings of $2.41 per share which beat the analyst consensus estimate of $2.26 by 6.64 percent. This is a 19.13 percent decrease over earnings of $2.98 per share from the same period last year. The company reported quarterly sales of $30.91 billion which beat the analyst consensus estimate of $30.84 billion by 0.23 percent. This is a 3.15 percent decrease over sales of $31.92 billion the same period last year.

Target Q4 2024 Adj EPS $2.41 Beats $2.26 Estimate, Sales $30.91B Beat $30.84B Estimate

UBS analyst William Grippin downgrades Ameresco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMRC#NYSE">AMRC</a>) from Buy to Sell and lowers the price target from $37 to $8.

AMRC

UBS Downgrades Ameresco to Sell, Lowers Price Target to $8

HC Wainwright &amp; Co. analyst Mike Colonnese maintains Hut 8 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) with a Buy and lowers the price target from $35 to $30.

HC Wainwright & Co. Maintains Buy on Hut 8, Lowers Price Target to $30

<a href="https://www.wsj.com/business/deals/honeywells-transformation-continues-with-2-2-billion-deal-for-pump-maker-b4695197" title="https://www.wsj.com/business/deals/honeywells-transformation-continues-with-2-2-billion-deal-for-pump-maker-b4695197">https://www.wsj.com/business/deals/honeywells-transformation-continues-with-2-2-billion-deal-for-pump-maker-b4695197</a>

Wall Street Journal Reported Honeywell Nears $2.2B All-Cash Deal to Acquire Pump Maker Sundyne From Warburg Pincus, Announcement Expected Tuesday

Albertsons Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACI#NYSE">ACI</a>) has <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44093556/albertsons-companies-inc-announces-ceo-succession-plan" rel="noreferrer noopener">announced a major leadership </a>shift as CEO Vivek Sankaran plans to retire on May 1, 2025.
Susan Morris, who is currently the Executive Vice President and Chief Operations Officer, will step into the role. On the same day, Morris will also assume a seat on the company's Board of Directors, replacing Sankaran.
With nearly 40 years of experience in the grocery retail sector, Susan Morris has held several leadership positions within Albertsons.
Since January 2018, she has been at the helm of the company's retail operations, managing over 2,200 locations across 34 states.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/25/03/44081963/ford-february-us-sales-slide-8-9-ev-sales-jump-15-details" rel="noreferrer noopener">Ford February US Sales Slide 8.9%, EV Sales Jump 15%: Details</a>
Her career includes roles such as Executive Vice President of Regional Operations and Division President in two distinct markets. Morris began her journey with Albertsons at a store in Denver, where she started her long-standing career.
&#8220;She is highly respected across the organization and industry, with a strong track record of operational success and passion for serving our customers and communities,&#8221; said Chair of the Albertsons Cos. Board of Directors, Jim Donald.
Outlook Reaffirmed: In addition to the leadership change announcement, Albertsons has<a href="https://www.benzinga.com/25/01/42874054/grocery-giant-albertsons-q3-sales-grow-as-pharmacy-products-shine" target="_blank" rel="noreferrer noopener"> reaffirmed its financial projections</a> for 2024. The company expects Identical sales growth to be in the range of 1.8% to 2.0%.
Adjusted EBITDA is forecasted to be between $3.95 billion and $3.99 billion. The anticipated adjusted net income per Class A share is expected to be between $2.25 and $2.31 (consensus $2.29), while capital expenditures are estimated at between $1.8 billion and $1.9 billion.
The company also projects an effective income tax rate between 15% and 16%.
Price Action: ACI shares closed lower by 1.66% at $20.69 on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/03/44074819/servicenow-unveils-ai-agents-for-telecoms-in-collaboration-with-nvidia" target="_blank" rel="noreferrer noopener">ServiceNow Unveils AI Agents For Telecoms In Collaboration With Nvidia</a></li>
</ul>
Image via Shutterstock.

Management

Grocery Giant Albertsons Names Susan Morris As New CEO

HC Wainwright &amp; Co. analyst Kevin Dede reiterates Canaan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAN#NASDAQ">CAN</a>) with a Buy and maintains $3 price target.

HC Wainwright & Co. Reiterates Buy on Canaan, Maintains $3 Price Target

Citigroup analyst Ralph Giacobbe upgrades Labcorp Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) from Neutral to Buy and raises the price target from $250 to $300.

Upgrades

Laboratory Corporation Of America Holdings

Citigroup Upgrades Labcorp Hldgs to Buy, Raises Price Target to $300

Press Releases

Aclarion to Participate in the 2024 Maxim Healthcare Virtual Summit

Events

Aclarion to Present at the Virtual Investor Summit Microcap Event on November 21st

Biotech

Aclarion Announces Nociscan Featured in RSNA Edition of Siemens MAGNETOM Flash

Aclarion to Showcase Groundbreaking NOCISCAN Technology at the Selby Spine Conference

Aclarion Announces CLARITY Trial for Nociscan Now Fully Funded

Aclarion Announces Northwestern Medicine as First CLARITY Trial Site

Legal

Aclarion Receives US Patent to Protect Expanded Applications of Magnetic Resonance Spectroscopy (MRS) Data Processing to Identify Pain and Infection Biomarkers Throughout the Body

Comments

Aclarion

Aclarion (ACON) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル